Literature DB >> 9089980

The kinetics of G-CSF mobilization of CD34+ cells in healthy people.

D F Stroncek1, M E Clay, G Herr, J Smith, W B Jaszcz, S Ilstrup, J McCullough.   

Abstract

When healthy people are given granulocyte colony stimulating factor (G-CSF) for 10 days the number of CD34+ cells in the peripheral blood begins to increase on the fourth day, reaches a maximum on the sixth day and then decreases. In this study, we further define the time and variability of peak mobilization of CD34+ cells. Twenty-two healthy people were given G-CSF (7.5 or 10 micrograms kg-1 day-1) subcutaneously each morning for 5 days and peripheral blood CD34+ cell counts were analysed immediately prior to the fourth (day 4) and fifth (day 5) G-CSF injection and 24 h after the fifth injection (Day 6). White blood cell (WBC) and neutrophil counts were greatest on day 6 [WBC = 43.8 +/- 13.9 x 10(9) L-1 (mean +/- 1 SD) and neutrophils = 36.6 +/- 12.8 x 10(9) L-1]. In contrast the CD34+ cell counts on day 6 (107 +/- 104 x 10(6) L-1) were less than on day 5 (128 +/- 136 x 10(6) L-1) (P = 0.048) but still greater than on day 4 (60.7 +/- 40.2 x 10(6) L-1) (P < 0.0001). The CD34+ cell counts of 10 donors were measured 2, 4 and 6 h after the fifth injection to determine if the counts increased further between days 5 and 6. The number of CD34+ cells in the blood on day 5 2 h after the fifth injection (193 +/- 277 x 10(6) L-1) was greater than the number prior to the injection (158 +/- 190 x 10(6) L-1), 4 h post-injection (139 +/- 158 x 10(6) L-1) and 6 h post-injection (170 +/- 236 x 10(6) L-1), but the differences were not significant (P = 0.29, 0.25 and 0.45). The number of CD34+ cells in the blood of 12 people were measured before and after the fourth G-CSF dose. Prior to the day 4 injection the CD34+ count was 61 +/- 40 x 10(6) L-1. At 2, 4 and 6 h the counts were 60 +/- 40, 61 +/- 29 and 64 +/- 30 x 10(6) L-1, respectively, and the differences were not significant (P = 0.99, P = 0.98, and P = 0.73). In conclusion, when healthy volunteers are given daily G-CSF injections, the number of mobilized CD34+ cells was the greatest on day 5, slightly less on day 6 and the least on day 4. If only one PBSC component is needed, PBSCs can be collected on day 5 after only 4 days of G-CSF. If PBSC components are collected on both days 5 and 6, the fifth dose can be given either before or after the collection of the first PBSC component.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9089980     DOI: 10.1046/j.1365-3148.1997.d01-75.x

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  15 in total

1.  Angiogenic cells can be rapidly mobilized and efficiently harvested from the blood following treatment with AMD3100.

Authors:  Rebecca M Shepherd; Benjamin J Capoccia; Steven M Devine; John Dipersio; Kathryn M Trinkaus; David Ingram; Daniel C Link
Journal:  Blood       Date:  2006-08-15       Impact factor: 22.113

Review 2.  Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand.

Authors:  Louis M Pelus
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

3.  Protecting the Health and Safety of Cell and Tissue Donors.

Authors:  David F Stroncek; Lee England
Journal:  ISBT Sci Ser       Date:  2015-04-01

Review 4.  Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors:  M P Rettig; G Ansstas; J F DiPersio
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

5.  Aerobic exercise in humans mobilizes HSCs in an intensity-dependent manner.

Authors:  Jeff M Baker; Joshua P Nederveen; Gianni Parise
Journal:  J Appl Physiol (1985)       Date:  2016-11-23

6.  Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.

Authors:  Giuseppe Milone; Giovanni Tripepi; Massimo Martino; Flavia Ancora; Benedetta Bartolozzi; Andrea Spadaro; Chiara Nozzoli; Alessia La Fauci; Irene Amico; Salvatore Leotta; Massimo Poidomani; Giuseppe Irrera; Pasquale Iacopino; Riccardo Saccardi; Stefano Guidi; Alberto Bosi
Journal:  Blood Transfus       Date:  2012-10-10       Impact factor: 3.443

7.  Human and mouse macrophages collaborate with neutrophils to kill larval Strongyloides stercoralis.

Authors:  Sandra Bonne-Année; Laura A Kerepesi; Jessica A Hess; Amy E O'Connell; James B Lok; Thomas J Nolan; David Abraham
Journal:  Infect Immun       Date:  2013-06-24       Impact factor: 3.441

8.  Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration.

Authors:  M E Horwitz; J P Chute; C Gasparetto; G D Long; C McDonald; A Morris; D A Rizzieri; K M Sullivan; N J Chao
Journal:  Bone Marrow Transplant       Date:  2011-11-14       Impact factor: 5.483

9.  Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury.

Authors:  Yedidya Saiman; JingJing Jiao; M Isabel Fiel; Scott L Friedman; Costica Aloman; Meena B Bansal
Journal:  Hepatol Res       Date:  2014-10-07       Impact factor: 4.288

10.  Granulocyte Colony-Stimulating Factor Use in Decompensated Cirrhosis: Lack of Survival Benefit.

Authors:  Cyriac A Philips; Philip Augustine; Sasidharan Rajesh; Rizwan Ahamed; Tom George; Guruprasad Padsalgi; Rajaguru Paramaguru; Gopakumar Valiathan; Solomon K John
Journal:  J Clin Exp Hepatol       Date:  2019-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.